Li Xue, Wang Fang, Jia Huijun, Lian Zhen, Ren Kai, Yuan Zhiyong, Wang Ping, Zhao Lujun
Department of Radiation Oncology, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention & Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin, 300060, China.
Department of Radiation Oncology, Affiliated Hospital of Hebei University, Baoding, 071000, China.
Future Oncol. 2022 Sep;18(27):3055-3065. doi: 10.2217/fon-2022-0491. Epub 2022 Aug 10.
To assess the efficacy and safety of inhibitors combined with (chemo)radiotherapy in unresectable, locally advanced non-small-cell lung cancer. A systematic review and meta-analysis of prospective trials was performed. Twenty-eight studies of 1640 patients were included. In patients harboring EGFR-sensitive mutations, the pooled objective response rate, 1-year overall survival rate and 1-year progression-free survival rate of EGFR-TKIs + (chemo)radiotherapy were 0.803, 0.766 and 0.554, respectively. Compared with chemoradiotherapy, the addition of inhibitors did not significantly increase the risk of grade ≥3 pneumonitis and esophagitis. EGFR-tyrosine kinase inhibitors combined with (chemo)radiotherapy are tolerable and the clinical benefit is promising, especially in patients with EGFR-sensitive mutations.
评估抑制剂联合（化疗）放疗用于不可切除的局部晚期非小细胞肺癌的疗效和安全性。对前瞻性试验进行了系统评价和荟萃分析。纳入了28项研究中的1640例患者。在携带表皮生长因子受体（EGFR）敏感突变的患者中，EGFR酪氨酸激酶抑制剂（EGFR-TKIs）联合（化疗）放疗的汇总客观缓解率、1年总生存率和1年无进展生存率分别为0.803、0.766和0.554。与放化疗相比，添加抑制剂并未显著增加≥3级肺炎和食管炎的风险。EGFR酪氨酸激酶抑制剂联合（化疗）放疗耐受性良好，临床获益前景广阔，尤其是在EGFR敏感突变患者中。
